Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 3/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | CTSC | P53634 | 2/20 | 0.48 |
| ▸ | ULK1 | O75385 | 4/20 | 0.48 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCND3 | P30281 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495081 | 0.93 | CDK4 (0.53) | BRD4FLT3CHEK1KITEGFR | |
| SCHEMBL3496765 | 0.91 | EGFR (0.55) | BRD4EGFRCTSCCDK4CCND3 | |
| SCHEMBL1743522 | 0.90 | BRD4 (0.46) | BRD4FLT3CHEK1KITULK1 | |
| SCHEMBL3496816 | 0.89 | TNK2 (0.51) | BRD4FLT3CHEK1EGFRSYK | |
| SCHEMBL3496128 | 0.89 | CHEK1 (0.48) | BRD4FLT3CHEK1KITEGFR | |
| SCHEMBL1743511 | 0.89 | BRD4 (0.52) | BRD4FLT3CHEK1KITEGFR | |
| SCHEMBL3494604 | 0.88 | BRD4 (0.56) | BRD4FLT3SYK | |
| SCHEMBL3495623 | 0.86 | BRD4 (0.59) | BRD4FLT3CDK4CCND3GSK3B | |
| SCHEMBL1741267 | 0.86 | CDK2 (0.53) | BRD4FLT3CHEK1KITEGFR | |
| SCHEMBL3497984 | 0.85 | ULK1 (0.51) | FLT3CHEK1KITULK1ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | BRD4 1173/4885FLT3 172/4885CHEK1 184/4885 |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | IL2, IL17A, IL23R | BRD4 664/4885FLT3 2318/4885CHEK1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.